表紙
市場調査レポート

糖尿病治療薬:世界の産業・市場・R&D・売上予測 (2015-2025年)

Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025

発行 Visiongain Ltd 商品コード 269884
出版日 ページ情報 英文 240 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.53円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
糖尿病治療薬:世界の産業・市場・R&D・売上予測 (2015-2025年) Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
出版日: 2015年05月06日 ページ情報: 英文 240 Pages
概要

当レポートでは、世界の糖尿病治療薬の市場について調査し、糖尿病および糖尿病治療の現状、主要薬剤区分および主要薬剤別の主要動向、市場収益の過去の推移と予測、主要国における動向、R&Dの動向、専門家へのインタビューなどをまとめています。

第1章 エグゼクティブサマリー

第2章 世界の糖糖尿病治療薬市場:イントロダクション

  • 市場区分
  • 糖尿病とは
  • 糖尿病の分類法
  • リスクファクター・症状・合併症
  • 糖尿病の診断基準
  • 世界・地域別の有病率・罹患率
  • 糖尿病における経済負担
  • アンメットニーズ
  • 主要薬剤クラス

第3章 世界の糖尿病治療薬市場の予測

  • 世界の糖尿病治療薬市場の実績
    • 薬剤クラス別
    • 売れ筋糖尿病治療薬
    • トップ10製薬業者
  • 世界の糖尿病治療薬市場:収益予測

第4章 ヒトインスリンおよび類似体市場の予測

  • 市場実績
  • 収益予測
  • 市場動向
  • Lantus (インスリンアスパルト - Sanofi)
  • NovoLog (インスリンアスパルト - Novo Nordisk)
  • Humalog (インスリンリスプロ - Eli Lilly)
  • Levemir (インスリンデテミル - Novo Nordisk)
  • Human Insulins (Novo Nordisk)
  • NovoMix (インスリンアスパルト - Novo Nordisk)
  • Humulin (インスリンイソフェン - Eli Lilly)

第5章 DPP-4阻害剤薬市場

  • 市場実績
  • 収益予測
  • Januvia (シタグリプチン - Merck & Co.)
  • Janumet (シタグリプチン&メトホルミン - Merck & Co.)
  • Galvus (ビルダグリプチン - Novartis)
  • Onglyza (サクサグリプチン - AstraZeneca)
  • Nesina (アログリプチン - 武田薬品工業/Furiex Pharmaceuticals)
  • Tradjenta (リナグリプチン - Eli Lilly and Boehringer Ingelheim)

第6章 スルホニル尿素市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Diamicron (グリクラジド - Servier)
  • Amaryl (グリメピリド - Sanofi)
  • Glucotrol XL (グリクラジド - Pfizer)

第7章 GLP-1受容体作動薬市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Victoza (リラグルチド - Novo Nordisk)
  • Byetta (エクセナチド - AstraZeneca)
  • Bydureon (エクセナチド - AstraZeneca)

第8章 α-グルコンシダーゼ阻害薬市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Glucobay (アカルボース - Bayer AG)
  • Basen (ボグリボース - 武田薬品工業)
  • Glyset (ミグリトール - Pfizer)

第9章 メグリチニド市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Prandin (レパグリニド - Novo Nordisk)
  • Starlix (ナテグリニド - Novartis)
  • Glufast (ミチグリニド - キッセイ薬品工業・武田薬品工業)

第10章 チアゾリジンジオン市場

  • 市場概要

第11章 SGLT2阻害薬市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Invokana (カナグリフロジン - Johnson & Johnson)
  • Forxiga (ダパグリフロジン - AstraZeneca)
  • Jardiance (エンパグリフロジン - Eli Lilly)

第12章 ビグアニド市場

  • 市場実績
  • 収益予測
  • 市場動向
  • Glucophage (メトホルミン - Merck & Co.)
  • Glumetza (塩酸メトホルミン - Santarus Inc.)
  • Fortamet (塩酸メトホルミン - Shionogi & Company)

第13章 主要国の糖尿病治療薬市場の予測

  • 主要国市場の実績
  • 主要国市場 - 収益予測
  • 米国
  • 日本
  • EU5カ国
  • 中国
  • インド
  • ロシア
  • ブラジル

第14章 糖尿病治療薬市場:開発パイプライン

第15章 糖尿病治療薬:世界の産業・市場・R&Dの分析

第16章 インタビュー調査

第17章 結論

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0043

Treating diabetes - benefit your influence by finding new R&D trends and sales prospects

Discover the future of antidiabetic medicines. For those treatments, now get new revenue predictions, also exploring research and development. Discover diabetes market size and business potentials. And assess results, trends, technologies, therapies and opportunities.

Visiongain's updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what's possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines' predicted revenue.

Forecasts to 2025 and other analyses explain and predict the diabetes treatment market

Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

That study also shows 90 tables, 91 charts and two interviews. Our work's purpose is to predict that industry's future, helping your research, analyses and decisions. See there how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities lie.

Though no such study covers everything on treating high blood sugar, the following sections show how our new investigation benefits your work.

image1

Forecasting of that world market and its segments - what does the future hold?

What are the secrets of that industry's progress? Where's it heading? Discover in our report overall world revenue prediction to 2025 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level:

  • Human insulins and analogues
  • Dipeptidyl peptidase-4 inhibitors (DPP-4)
  • Biguanides
  • Glucagon-like peptide-1 receptor agonists (GLP-1)
  • Sulfonylureas.

And these treatment categories:

  • Thiazolidinediones
  • Alpha-glucosidase inhibitors
  • Meglitinides
  • Sodium-glucose co-transporter-2 inhibitors (SGLT2)
  • Other agents (grouped).

There assess outlooks for revenue expansion, hearing where you can profit. Find the diabetes market size from 2015. You investigate competition and rising sales. And you examine technological, clinical and commercial possibilities.

Also find top medicines' revenue potentials.

image2

Predictions of leading products' sales - see what's possible, where you can gain

How will individual drugs for elevated blood sugar perform to 2025 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:

  • Lantus
  • Januvia
  • NovoLog and NovoMix
  • Levemir
  • Humalog
  • Victoza
  • Janumet
  • Humulin.

There you find drugs and years with highest predicted sales. You also examine competitors. So discover what's happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

That work also gives geographical sales predictions.

National markets - what outlooks for treatment demand and revenues?

In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2015 to 2025. See where, how and what's possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy and Spain (EU5)
  • BRIC nations - Brazil, Russia, India and China.

There you explore progress, needs and opportunities. What events change that market and outlooks for payers and patients? Our work shows you, discussing trends and demands.

image3

Events affecting developers, producers and sellers of those metabolic treatments

That report also explains issues, forces and events affecting the antidiabetics industry and market from 2015, including these influences:

  • Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
  • Governmental investment and collaboration between pharmaceutical companies
  • Combination therapies for type 2 diabetes
  • Competition from biosimilars and generic drugs - approvals and product launches.

And these issues, among others:

  • Disease incidence and prevalence
  • Risk factors - obesity and pre-diabetes, related metabolic conditions
  • Drug delivery - technologies for introducing insulin and oral drugs
  • New classes of antidiabetic medications and regulatory challenges
  • Type 1 diabetes vaccine - new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you investigate what stimulates and restrains that biopharma, affecting its results. Also see prospects for small-molecule therapies.

Analysis of firms and potential for rising sales - what overall revenues possible?

What happens next? Our study predicts that world market will rise to $72.6bn in 2019, with high, expanding revenues from 2015 to 2025. See what's possible.

Our analysis covers organisations shaping that industry:

  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • AstraZeneca
  • Merck & Co.

Also investigate these leading companies, among other firms, including specialists in metabolic disorders:

  • Boehringer Ingelheim
  • Takeda
  • Sanofi
  • Bayer
  • Pfizer.

And gain interviews with two other authorities on diabetes treatments. Our survey explores issues affecting that healthcare industry's present and future.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

Ways Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025 helps

In particular, our new investigation gives this knowledge to benefit your work:

  • Antidiabetic drug revenues to 2025 at overall world level, for 9 therapeutic submarkets and 31 products - assess outlooks for production, marketing and sales
  • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for demand and revenue potentials
  • Prospects for established competitors, rising companies and new entrants - explore portfolios, opinions, results, strategies, technologies and outlooks for success
  • Review of R&D pipelines - examine progress in research and development, finding technological and medical prospects
  • Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete, gain advantages and succeed.

That study, done in-house by our UK-based analysts, helps your knowledge and authority.

Information found nowhere else, helping your searches, analyses and plans - your success

And how can you be sure we know our subject? That's a fair point. We do so by getting the most from data, interpreting its meaning for business now and the future.

We digest publications and survey authorities, saving you time and difficulty, helping your planning and decisions. You hear what's happening, getting a feel for companies' prospects.

And our study gives independent analysis. There you get competitive intelligence found only in our report, finding where progress, money and opportunities lie. See what's possible.

Does that work answer every question? No, though it assesses diabetes medicines, their producers and commercial outlooks in detail. That way you find potential gains, discovering opportunities to harness, as well as benefiting your influence.

Trying our investigation now lets you see opportunities and revenue predictions

So with our survey you're less likely to fall behind in knowledge or miss opportunity. There find how to save time and effort, also benefiting your insight, authority and competing.

Our new analysis helps professionals like you assess the market for diabetes treatments. There you explore trends, discussions and sales forecasting. Avoid missing out in knowledge. Benefit by getting that report here now.

Table of Contents

1. Report Overview

  • 1.1 Introduction to that Industry and Market
  • 1.2 Main Report Findings
  • 1.3 This Study Provides the Following Knowledge
  • 1.4 Why You Should Read This Report
  • 1.5 How This Report Delivers
  • 1.6 Main Questions Answered
  • 1.7 Who is This Study For?
  • 1.8 Research and Analysis Methods
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Global Diabetes Drug Market: Introduction

  • 2.1 World Diabetes Drugs Market Segmentation
  • 2.2 What is Diabetes?
  • 2.3 How is Diabetes Classified
  • 2.4 Risk Factors, Disease Symptoms and Complications
  • 2.5 Criteria for the Diagnosis of Diabetes
  • 2.6 World and Regional Diabetes Incidence and Prevalence
  • 2.7 The Economic Burden of Diabetes
  • 2.8 Unmet Need
  • 2.9 Leading Classes of Diabetic Medications
    • 2.9.1 Type 1 Medication
      • 2.9.1.1 Insulin
      • 2.9.1.2 Surgical Options
    • 2.9.2 Type 2 Medication
      • 2.9.2.1 Alpha-glucosidase Inhibitors
      • 2.9.2.2 Biguanides
      • 2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
      • 2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
      • 2.9.2.5 Thiazolidinediones
      • 2.9.2.6 Sulfonylureas
      • 2.9.2.7 Meglitinides
      • 2.9.2.8 Other Injectable Medications
      • 2.9.2.9 Combination Drug Therapies for Type 2 Diabetes

3. The World Diabetes Drugs Market, 2015-2025

  • 3.1 The World Diabetes Drug Market, 2014
    • 3.1.1 Diabetes Treatment Market by Drug Class, 2014
    • 3.1.2 Top Selling Diabetes Drugs, 2014
    • 3.1.3 Generic Anti Diabetes Drugs, 2014
    • 3.1.4 Top 10 Diabetes Drug Producers, 2014
  • 3.2 World Diabetes Drugs Market: Revenue Forecast, 2015-2025

4. Human Insulin and Analogues Market, 2015-2025

  • 4.1 Insulin and Insulin Analogues Drugs, 2014
  • 4.2 Insulin and Insulin Analogues: Revenue Forecast, 2015-2025
  • 4.3 Insulin and Insulin Analogues: Market Trends, 2015-2025
    • 4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
    • 4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
  • 4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2015-2025
  • 4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2015-2025
  • 4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2015-2025
  • 4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast,2015-2025
  • 4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2015-2025
  • 4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2015-2025
  • 4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2015-2025

5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2015-2025

  • 5.1 DPP-4 Market, 2014
  • 5.2 DPP-4 Inhibitors Revenue Forecast, 2015-2025
  • 5.3 Januvia (Sitagliptin; Merck & Co.): Revenue Forecast, 2015-2025
  • 5.4 Janumet (Sitagliptin and Metformin; Merck & Co.): Revenue Forecast, 2015-2025
  • 5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2015-2025
  • 5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2015-2025
  • 5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2015-2025
  • 5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2015-2025

6. Sulfonylureas Market, 2015-2025

  • 6.1 Sulfonylureas Market, 2014
  • 6.2 Sulfonylureas: Revenue Forecast, 2015-2025
  • 6.3 Sulfonylureas: Market Trends 2015-2025
    • 6.3.1 New Opportunities for Sulfonylureas in Emerging Markets
    • 6.3.2 Side Effects and Competitor Drugs Will Affect Sales
  • 6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2015-2025
  • 6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2015-2025
  • 6.6 Glucotrol (Glipizide; Pfizer): Revenue Forecast, 2015-2025

7. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, 2015-2025

  • 7.1 GLP-1 Receptor Agonists Market, 2014
  • 7.2 GLP-1 Receptor Agonists Revenue Forecast, 2015-2025
    • 7.2.1 GLP-1 Receptor Agonists: Market Trends, 2015-2025
    • 7.2.2 Promising New Approvals in the GLP-1 Class
    • 7.2.3 GLP-1 Agonists and Weight Loss Results May Boost the Revenues
  • 7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2015-2025
  • 7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025
  • 7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2015-2025

8. Alpha-glucosidase Inhibitors Market, 2015-2025

  • 8.1 Alpha-glucosidase Inhibitors Market, 2014
  • 8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2015-2025
    • 8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2015-2025
      • 8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
      • 8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
  • 8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2015-2025
  • 8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2015-2025
  • 8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2015-2025

9. Meglitinides Market, 2015-2025

  • 9.1 Meglitinides Market, 2014
  • 9.2 Meglitinides: Revenue Forecast, 2015-2025
    • 9.2.1 Meglitinides: Market Trends, 2015-2025
      • 9.2.1.1 Combination Therapy: New Future for Meglitinides?
  • 9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2015-2025
  • 9.4 Sarlix (Nateglinide; Novartis): Revenue Forecast, 2015-2025
  • 9.5 Glufast (Acarbose; Bayer): Revenue Forecast, 2015-2025

10. Thiazolidinediones Market, 2014

  • 10.1 Thiazolidinediones Market Overview, 2014

11. Sodium-glucose Co-transporter-2 (SGLT2) Inhibitors Market, 2015-2025

  • 11.1 SGLT2 Inhibitors Market, 2014
  • 11.2 SGLT2 Revenue Forecast, 2015-2025
    • 11.2.1 SGLT2 Market Trends, 2015-2025
  • 11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2015-2025
  • 11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2015-2025
  • 11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2015-2025

12. Biguanides Market, 2015-2025

  • 12.1 Biguanides Market, 2014
  • 12.2 Biguanides: Revenue Forecast, 2015-2025
    • 12.2.1 Biguanides: Market Trends, 2015-2025
    • 12.2.2 Metformin: Delay of Diabetes
    • 12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
  • 12.3 Glucophage (Metformin; Merck & Co): Revenue Forecast, 2015-2025
  • 12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2015-2025
  • 12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2015-2025

13. National Markets for Diabetes Drugs, 2015-2025

  • 13.1 Leading National Markets for Diabetes Drugs, 2014
  • 13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2015-2025
  • 13.3 The US to Sustain its Market Leadership: Revenue Forecast 2015-2025
    • 13.3.1 High Diabetes Prevalence within a Complex Healthcare System
  • 13.4 The Japanese Market, Revenue Forecast 2015-2025
    • 13.4.1 Increased Governmental Investment Will Drive Market Growth
    • 13.4.2 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
    • 13.4.3 Novel Treatment Options in Japan
  • 13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2014
    • 13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market: Revenue Forecasts, 2015-2025
      • 13.5.1.1 Germany: Disease Treatment Measures Require Improvement - Revenue Forecast, 2015-2025
      • 13.5.1.2 Great Standard of Care and Regulatory Reforms in France - Revenue Forecast 2015-2025
      • 13.5.1.3 Austerity Measures in Spain Discourage Companies - Revenue Forecast 2015-2025
      • 13.5.1.4 UK: High Burden of Diabetes Costs on the UK NHS
      • 13.5.1.5 Italy: Stable Market with Good Standards of Care - Revenue Forecast, 2015-2025
  • 13.6 China: The World's Largest Diabetic Population - Revenue Forecast, 2015-2025
    • 13.6.1 Presence of Multinational Companies and the Power of Buyers
    • 13.6.2 Disparity in Regional Health Spending
    • 13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
  • 13.7 The Indian Market: Revenue Forecast, 2015-2025.
    • 13.7.1 Focus on the Rural Population
  • 13.8 Introduction of Novel Therapies in the Russian Federation - Revenue Forecast, 2015-2025
    • 13.8.1 High Out of Pocket Costs Reduce Compliance
  • 13.9 Brazil: Improved Access to Care in Rural Areas - Revenue Forecast, 2015-2025
    • 13.9.1 Localized Insulin Production in Brazil
    • 13.9.2 Diabetes Awareness Initiatives will Increase Market Potential

14. Diabetes Drug Market R&D Pipeline, 2015

  • 14.1 New Diabetes Drugs Approvals and Leading Companies' Developments, 2015
    • 14.1.1 Novo Nordisk
    • 14.1.2 Eli Lilly & Boehringer Ingelheim
    • 14.1.3 AstraZeneca
  • 14.2 Human Insulins and Analogues: New Approvals
    • 14.2.1 Insulin Glargine (LY2963016 Eli Lilly and Boehringer Ingelheim): US Approval Delay May Trigger High Revenues
    • 14.2.2 Insulin Glargine (U300 Sanofi): Will it Replace Lantus?
    • 14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin. Will it Reach $1bn Sales?
  • 14.3 Human Insulins and Analogues: Pipeline Developments, 2015
    • 14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
    • 14.3.2 Basal Insulin Peglispro-BIL (Eli Lilly): Holding Promise - What Will More Testing Bring?
    • 14.3.3 MK-1293 (Merck & Co. and Biogen Idec): Another Biosimilar of Lantus on the Way
    • 14.3.4 OG217SC (Novo Nordisk)
  • 14.4 DPP-4 Inhibitors: Pipeline Developments
    • 14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex) Pharmaceuticals): Approved in Japan
    • 14.4.2 Omarigliptin (MK-3102; Merck & Co.)
    • 14.4.3 ARI-2243 (Arisaph)
  • 14.5 GLP-1: New Approvals and Pipeline, 2015
    • 14.5.1 Trulicity (Dulaglutide; Eli Lilly): Does it have the Potential to Reach Blockbuster Status?
    • 14.5.2 Tanzeum (Albiglutide; GSK)
    • 14.5.3 Semaglutide (NN9535; Novo Nordisk)
    • 14.5.4 Xultophy (formerly IDegLira; Novo Nordisk)
    • 14.5.5 ITC650 (Intarcia Therapeutics)
  • 14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2015
    • 14.6.1 Suglat (Ipragliflozin; Astellas Pharma/Kotobuki)
    • 14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
    • 14.6.3 Lusefi (Luseogliflozin; Taisho Pharmaceutical)
  • 14.7 Other Anti Diabetes Drugs: Pipeline Developments, 2015
    • 14.7.1 DM199 (DiaMedica)
    • 14.7.2 DiaPep277 (Andromeda Biotech)
    • 14.7.3 Glucokinase Activators
    • 14.7.4 ZYGK1 (Zydus Cadila Healthcare)
    • 14.7.5 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)

15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2015-2025

  • 15.1 SWOT Analysis of the Diabetes Drug Market, 2015-2025
  • 15.2 Strengths
    • 15.2.1 Promising Research and Development
    • 15.2.2 Secondary Indications
    • 15.2.3 Biological Drugs are Tougher to Copy and Offer Variety
    • 15.2.4 Market Competition
  • 15.3 Weaknesses
    • 15.3.1 Lack of Disease Awareness
    • 15.3.2 Tougher Reimbursement Rules
    • 15.3.3 Increased Risk of Cardiovascular Complications
    • 15.3.4 Rising Cost of Drug Development
  • 15.4 Opportunities
    • 15.4.1 Rising Disease Prevalence
    • 15.4.2 Emerging National Markets Hold Great Potential
    • 15.4.3 Novel Insulin Delivery Methods
    • 15.4.4 New Classes of Anti Diabetes Drugs
  • 15.5 Threats
    • 15.5.1 Type 1 Diabetes Vaccine
    • 15.5.2 Increased Popularity of Other Therapies
    • 15.5.3 Generic Drugs: Patent Expiries and Rising Competition
    • 15.5.4 Regulatory Barriers - Challenges Getting Drug Approval
  • 15.6 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
    • 15.6.1 Social Developments
    • 15.6.2 Technological Advances
    • 15.6.3 Economic Factors
    • 15.6.4 Political Issues

16. Research Interviews

  • 16.1 Interview with an Academic Involved in Diabetes R&D
    • 16.1.1 The Insulin Drug Market
    • 16.1.2 Novel Delivery Technologies
    • 16.1.3 Future Developments and Market Prospects
  • 16.2 Interview with James Anderson, Generex Biotechnology Corporation
    • 16.2.1 The Current Diabetes Drug Market
    • 16.2.2 Generex's Oral-lyn™ Product and Buccal Drug Delivery

17. Conclusions from the Research and Analysis

  • 17.1 The Diabetes Market - Trends Shaping Those Treatments
  • 17.2 Outlook of the Worlds Diabetes Drug Industry, 2015-2025
  • 17.2.1 Insulin Will Continue to Dominate the Market
  • 17.3 Regional Outlooks for That Market, 2015-2025
  • 17.4 Future Opportunities

List of Tables

  • Table 1.1 Leading National Diabetes Drugs Market Forecast, 2015-2025 ($bn, AGR %), 2014-2025
  • Table 1.2 Foreign Currency Exchange Rates Utilised: Exchange Rate to $USD, 2014
  • Table 2.1 Types of Injectable Insulin, 2015
  • Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2015
  • Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2015
  • Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2015
  • Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2014
  • Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drug Class, 2014
  • Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2014
  • Table 3.4 Top 3 Human Insulin Producers: Sales ($m), 2014
  • Table 3.5 Top 10 Diabetes Drugs Producers: Sales ($m), 2014
  • Table 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn) by Drug Class, 2014-2019
  • Table 3.7 World Diabetes Drugs Market: Revenue Forecasts ($bn) by Drug Class,
  • 2020-2025
  • Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 4.3 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 4.4 Top 3 Human Insulin Producers: Sales ($m), 2014
  • Table 4.5 Lantus: Drug Revenue Forecast ($bn), 2014-2025
  • Table 4.6 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
  • Table 4.7 Humalog: Drug Revenue Forecast ($bn), 2014-2025
  • Table 4.8 Levemir: Revenue Forecast ($bn), 2014-2025
  • Table 4.9 Human Insulins Novo Nordisk: Revenue Forecast ($bn), 2014-2025
  • Table 4.10 NovoMix: Revenue Forecast ($bn), 2014-2025
  • Table 4.11 Humulin: Revenue Forecast ($bn), 2014-2025
  • Table 5.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 5.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 5.3 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
  • Table 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
  • Table 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
  • Table 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
  • Table 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
  • Table 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
  • Table 6.1 Sulfonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 6.2 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 6.3 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
  • Table 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
  • Table 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
  • Table 7.1 GLP-1: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 7.2 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 7.3 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
  • Table 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
  • Table 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
  • Table 8.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 8.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 8.3 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
  • Table 8.5 Basen: Revenue Forecast ($bn), 2014-2025
  • Table 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
  • Table 9.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 9.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 9.3 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
  • Table 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
  • Table 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
  • Table 10.1 Thiazolidinediones: Revenues ($bn), 2014
  • Table 11.1 SGLT2 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 11.2 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 11.3 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
  • Table 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
  • Table 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
  • Table 12.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014
  • Table 12.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019
  • Table 12.3 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025
  • Table 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
  • Table 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
  • Table 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
  • Table 13.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2014
  • Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2014-2019
  • Table 13.3 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2020-2025
  • Table 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
  • Table 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
  • Table 13.6 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($bn) and Market Share (%) by Country, 2014
  • Table 13.7 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts ($bn), 2014-2019
  • Table 13.8 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2020-2025
  • Table 13.9 Germany: Revenue Forecast ($bn), 2014-2025
  • Table 13.10 France: Revenue Forecast ($bn), 2014-2025
  • Table 13.11 Spain: Revenue Forecast ($bn), 2014-2025
  • Table 13.12 United Kingdom: Revenue Forecast ($bn), 2014-2025
  • Table 13.13 Italy: Revenue Forecast ($bn), 2014-2025
  • Table 13.14 China: Revenue Forecast ($bn), 2014-2025
  • Table 13.15 India: Revenue Forecast ($bn), 2014-2025
  • Table 13.16 Russia: Revenue Forecast ($bn), 2014-2025
  • Table 13.17 Brazil: Revenue Forecast ($bn), 2014-2025
  • Table 14.1 FDA Approved Anti Diabetes Drugs, 2014
  • Table 14.2 Expected FDA Approvals for Anti Diabetes Drugs, 2015 and 2016
  • Table 17.1 The Global Diabetes Drugs Market: Overall Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
  • Table 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2019 and 2025
  • Table 17.3 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

List of Figures

  • Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2015
  • Figure 2.2 Diabetes Drugs Sub-market Segmentation, 2015
  • Figure 2.3 Diabetes Types and Classification, 2015
  • Figure 2.4 Diabetes Causes, 2015
  • Figure 2.5 Diabetes Regional Prevalence (population million), 2014
  • Figure 2.6 Diabetes Prevalence and Undetected Prevalence (%) by Region, 2014
  • Figure 2.7 World Number of Diabetics (population million), 2014-2025
  • Figure 3.1 World Diabetes Drugs Market: Market Share (%) by type of Medication, 2014
  • Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2014
  • Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2014
  • Figure 3.4 Top 10 Diabetes Drugs Producers vs Other Manufacturers: Market Share (%), 2014
  • Figure 3.5 Top 10 Diabetes Drugs Producers: Market Share (%), 2014
  • Figure 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2015
  • Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2014
  • Figure 4.2 Human Insulins and Analogues: Revenue Forecast ($bn), 2014-2025
  • Figure 4.3 Lantus: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.4 NovoLog: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.5 Humalog: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.6 Levemir: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.7 Human Insulins Novo: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.8 NovoMix: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 4.9 Humulin: Drug Revenue Forecast ($bn), 2014-2025
  • Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2014
  • Figure 5.2 DPP-4 Inhibitors: Sales ($bn) for Leading Drugs, 2014
  • Figure 5.3 DPP-4 Inhibitors: Revenue Forecast ($bn), 2014-2025
  • Figure 5.4 Januvia: Revenue Forecast ($bn), 2014-2025
  • Figure 5.5 Janumet: Revenue Forecast ($bn), 2014-2025
  • Figure 5.6 Galvus: Revenue Forecast ($bn), 2014-2025
  • Figure 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025
  • Figure 5.8 Nesina: Revenue Forecast ($bn), 2014-2025
  • Figure 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025
  • Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2014
  • Figure 6.2 Sulfonylureas: Sales ($bn) for Leading Drugs, 2014
  • Figure 6.3 Sulfonylureas: Revenue Forecast ($bn), 2014-2025
  • Figure 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025
  • Figure 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025
  • Figure 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025
  • Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2014
  • Figure 7.2 GLP-1: Sales ($bn) for Leading Drugs, 2014
  • Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($bn), 2014-2025
  • Figure 7.4 Victoza: Revenue Forecast ($bn), 2014-2025
  • Figure 7.5 Byetta: Revenue Forecast ($bn), 2014-2025
  • Figure 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025
  • Figure 8.1 Alpha-glucosidase Inhibitors: Revenue Sales ($bn), 2014
  • Figure 8.2 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2014
  • Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($bn), 2014-2025
  • Figure 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025
  • Figure 8.5 Basen: Revenue Forecast ($bn), 2014-2025
  • Figure 8.6 Glyset: Revenue Forecast ($bn), 2014-2025
  • Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2014
  • Figure 9.2 Meglitinides: Market Sales ($bn) for Leading Drugs, 2014
  • Figure 9.3 Meglitinides: Revenue Forecast ($bn), 2014-2025
  • Figure 9.4 Prandin: Revenue Forecast ($bn), 2014-2025
  • Figure 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025
  • Figure 9.6 Glufast: Revenue Forecast ($bn), 2014-2025
  • Figure 10.1 Thiazolidinediones: Sales ($bn), 2014
  • Figure 11.1 SGLT2 Inhibitors: Sales ($bn) for Leading Drugs, 2014
  • Figure 11.2 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2014
  • Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($bn), 2014-2025
  • Figure 11.4 Invokana: Revenue Forecast ($bn), 2014-2025
  • Figure 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025
  • Figure 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025
  • Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2014
  • Figure 12.2 Biguanides: Sales ($bn) for Leading Drugs, 2014
  • Figure 12.3 Biguanides: Revenue Forecast ($bn), 2014-2025
  • Figure 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025
  • Figure 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025
  • Figure 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025
  • Figure 13.1 The Global Diabetes Drugs Market: Revenues ($bn) by Region, 2014
  • Figure 13.2 Top 3 Global Markets vs BRIC Countries: Market Shares (%), 2014
  • Figure 13.3 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2014
  • Figure 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
  • Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025
  • Figure 13.6 EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($bn) by Country, 2014
  • Figure 13.7 EU5 (Germany, France, UK, Italy, Spain) Countries: Market Shares (%) by Country, 2014
  • Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries Market Global and EU5 Market Share (%), 2014
  • Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2014-2025
  • Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($bn), 2014-2025
  • Figure 13.11 Germany: Revenue Forecast ($bn), 2014-2025
  • Figure 13.12 France: Revenue Forecast ($bn), 2014-2025
  • Figure 13.13 Spain: Revenue Forecast ($bn), 2014-2025
  • Figure 13.14 United Kingdom: Revenue Forecast ($bn), 2014-2025
  • Figure 13.15 Italy: Revenue Forecast ($bn), 2014-2025
  • Figure 13.16 China: Revenue Forecast ($bn), 2014-2025
  • Figure 13.17 India: Revenue Forecast ($bn), 2014-2025
  • Figure 13.18 Russia: Revenue Forecast ($bn), 2014-2025
  • Figure 13.19 Brazil: Revenue Forecast ($bn), 2014-2025
  • Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2015-2025
  • Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2015-2025
  • Figure 17.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025
  • Figure 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025

Companies Listed

  • Actavis
  • Alphapharm
  • American Diabetes Association
  • Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
  • Andromeda Biotech
  • Arisaph
  • Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Biocon
  • Blue Cross
  • Bristol-Myers Squibb
  • Biogen Idec
  • Boehringer Ingelheim
  • Boston Therapeutics
  • Chugai Pharmaceutical
  • Diabetes UK
  • DiaMedica
  • Diamyd Medical
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • Express Scripts
  • Food and Drug Administration (US FDA)
  • Franco-Indian Pharmaceuticals
  • Furiex Pharmaceuticals
  • Genentech
  • Generex Biotechnology Corporation
  • GlaxoSmithKline (GSK)
  • Glenmark Pharmaceuticals
  • Google
  • Human Genome Sciences
  • Intarcia
  • International Diabetes Federation (IDF)
  • Janssen (subsidiary of J&J)
  • Johnson & Johnson (J&J)
  • Lupin
  • Kissei Pharmaceuticals
  • Kotobuki Pharma
  • Kowa
  • MannKind Corporation
  • Mascot Health Series
  • Merck & Co.
  • Merck Serono
  • Ministry of Health (MoH, Germany)
  • Ministry of Health, Labour and Welfare (MHLW, Japan)
  • MSD KK (Asian subsidiary of Merck & Co.)
  • Mylan
  • National Health Service (NHS, UK)
  • National Institute of Health and Clinical Excellence (NICE, UK)
  • Novartis
  • Novo Nordisk
  • Ono Pharmaceuticals
  • Oramed Pharmaceuticals
  • Patheon
  • Pfizer
  • Ranbaxy Laboratories
  • Roche
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus (bought by Salix Pharmaceuticals)
  • Servier
  • Shantha Biotechnics (acquired by Sanofi)
  • Shionogi Pharmaceuticals
  • Shreya Life Sciences
  • Stanford University School of Medicine
  • Sun Pharma
  • Takeda
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries
  • Transdermal Specialities
  • United States Diabetes Prevention Program (DPP)
  • World Health Organization (WHO)
  • Yabao Pharmaceutical
  • Zydus Cadila
Back to Top